Preliminary evaluation of the ongoing EMN22-trial (daratumumab monotherapy, addition of dexamethasone and bortezomib from the fourth cycle in the case of insufficient response) revealed a median OS of 9.4 months.25 There is a recent short report of a median OS of more than 12 months in Mayo ...
Daratumumab is an effective therapy in multiple myeloma (MM). We assessed whether daratumumab retreatment may re-induce significant responses and which pat
In conclusion, while DBI is efficacious in SR patients, there is insufficient data to support a benefit in HiR-MM.doi:10.1016/j.critrevonc.2020.103211Lip Leong ChongYu Yang SoonCinnie Yentia SoekojoMelissa OoiSanjay de MelCritical Reviews in Oncology/Hematology...
Multiple myelomaDaratumumabElotuzumabImmune microenvironmentElotuzumab-based regimens are sometimes selected for multiple myeloma treatment after daratumumab-based regimens. However, there has been insufficient discussion on the efficacy of elotuzumab after daratumumab. We used Kansai Myeloma Forum registration data...
Preliminary evaluation of the ongoing EMN22-trial (daratumumab monotherapy, addition of dexamethasone and bortezomib from the fourth cycle in the case of insufficient response) revealed a median OS of 9.4 months.25 There is a recent short report of a median OS of more than 12 months in Mayo ...